Cardiothoracic & vascular anaesthesia
Randomized Controlled: Trial of New Oral Anticoagulants Versus Warfarin for Postcardiac Surgery Atrial Fibrillation: The NEW-AF Trial
Authors' conclusion
Treatment with rivaroxaban in new-onset atrial fibrillation after cardiac surgery did not decrease length of stay compared with warfarin.
Study context
- Population
- Patients with new-onset atrial fibrillation (AF) after cardiac surgery
- Participants
- 100 patients
- Comparison
- Rivaroxaban vs warfarin
- Rivaroxabann = 50
- Warfarinn = 50reference
- Primary endpoint
- Length of stay (LOS) from day of surgery to discharge
Methodological detailspragmatic, prospective
- Pragmatic
- Prospective
Primary result
As reported in the abstract
P = 0.460
Further findings
LOS from initiation of anticoagulation to discharge
P = 0.738
Mobility issues (EuroQol-5D-3L) · 2 weeks after discharge
P = 0.021
| Outcome | Rivaroxaban | Warfarin | P value |
|---|---|---|---|
| INR at discharge | — not stated in the abstract | mean 1.68 (SD 0.5) | |
| Patient-reported convenience · 2 weeks after dischargeSignificantly higher scores with rivaroxaban | P < 0.001 | ||
| Overall perception of anticoagulation experience · 2 weeks after dischargeBetter with rivaroxaban | P = 0.006 | ||
| Treatment satisfaction · 2 weeks after dischargeSimilar in both groups | P = 0.494 |
— not stated in the abstract
Safety
Minor bleeding · none required blood transfusion
P = 0.617
| Outcome | Rivaroxaban | Warfarinevents | P value |
|---|---|---|---|
| Major bleeding, stroke, other arterial thromboembolism · 30 days postdischarge | 0 events | 0 | |
| Pericardial effusion requiring drainage | 2% | 0 | P = 1.000 |
Original publication
Randomized Controlled: Trial of New Oral Anticoagulants Versus Warfarin for Postcardiac Surgery Atrial Fibrillation: The NEW-AF Trial. Ann Surg. Published 24 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →